Dr. Hyung L. Kim

Claim this profile

Cedars Sinai Medical Center

Studies Prostate Cancer
Studies Kidney Cancer
2 reported clinical trials
7 drugs studied

Affiliated Hospitals

Image of trial facility.

Cedars-Sinai Medical Center

Image of trial facility.

Cedars-Sinai Cancer - Tarzana

Clinical Trials Hyung L. Kim is currently running

Image of trial facility.

Vytorin

for Prostate Cancer

To test the hypothesis that intensive cholesterol lowering (iCL) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase II trial in prostate cancer patients who are in active surveillance and undergoing a planned surveillance biopsy in 3-6 months. Eligible patients will initiate iCL with Vytorin®(group 1, 2, and 3), an FDA-approved combination of ezetimibe and simvastatin used to lower atherogenic low density lipoprotein cholesterol (LDL-C) or Ezetimibe (group 4). Starting dose will be determined by current statin use and LDL-C levels. Dose modifications of VYTORIN will be employed with the goal of achieving LDL-C \<70 mg/dl. Dose adjustment is not allowed for ezetimibe.

Recruiting

1 award

Phase 2

2 criteria

Image of trial facility.

Immunotherapy With or Without Surgery

for Kidney Cancer

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.

Recruiting

2 awards

Phase 3

16 criteria

More about Hyung L. Kim

Clinical Trial Related

1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Hyung L. Kim has experience with

  • Intensive Cholesterol-Lowering Therapy
  • Avelumab
  • Axitinib
  • Cytoreductive Nephrectomy
  • Ipilimumab
  • Nivolumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Hyung L. Kim specialize in?

Is Hyung L. Kim currently recruiting for clinical trials?

Are there any treatments that Hyung L. Kim has studied deeply?

What is the best way to schedule an appointment with Hyung L. Kim?

What is the office address of Hyung L. Kim?

Is there any support for travel costs?